Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3

Prostate Cancer Risk in Relation to a Single Nucleotide Polymorphism in the Insulin-like Growth Factor-binding Protein-3 (IGFBP3) Gene: a Meta-analysis

“…Second, unavailable details of race subdistribution in two studies prevented themselves from inclusion for subgroup analysis, which lead to insufficient samples in Africans and Asians subgroups compared with Caucasians (Nam et al, 2003;Li et al, 2004). Besides, it should be noteworthy that our conclusion actually owed much to Safarinejad's report (Safarinejad et al, 2011) with the most prominently positive result of all. While most other included studies yielded insignificant results, which meant our conclusion was seemingly less robust.…”

“…While most other included studies yielded insignificant results, which meant our conclusion was seemingly less robust. Recently, it has been reported that IGFBP3 as a multifunctional anti-proliferative protein gets involved in benign prostatic hyperplasia (BPH) development in a similar way with PCa (Neuhouser et al, 2008;Safarinejad et al, 2011), suggesting that it was possible for some BPH cases to be improperly grouped as controls, not to mention the asymptomatic or underdiagnosed PCa cases. On the other hand, the widely accepted hypothesis that circulating concentration of IGFBP3 runs inversely with PCa risk has been more and more challenged by case-control studies (Severi et al, 1999;Li et al, 2004;Hong et al, 2008).…”

Insulin resistance and cancer: the role of insulin and IGFs

“…A comparable study has revealed a correlation between zinc, IGF1, and IGFBP3 concentrations, and prostate-specific antigen in prostate cancer, and findings have indicated that zinc, IGF1, and IGFBP3 can be useful in early diagnosis of prostate cancer (Darago et al 2011). In addition, other investigators reported that IGFBP3 gene polymorphism would be associated with the susceptibility to develop prostate cancer (Safarinejad et al 2011a). A report from Price et al (2012) indicates that increases in circulating IGF1 levels are associated with a significantly increased risk for prostate cancer development.…”

<b><i>IGFBP-3</i></b> Promoter Polymorphism -202A>C (rs2854774) Contributes to Prostate Cancer Risk: Evidence Based on 9,482 Subjects

“…IGFBP-3 functions normally as an inhibitor of the IGF's action by blocking the binding of IGF to its receptor. Furthermore, several studies have shown that the IGFBP-3 -202A>C polymorphism was associated with circulating IGFBP-3 concentration, with the CC genotype associated with the lowest levels in PCa patients [16,17]. In our present study, it is also found that individuals with the variant homozygote genotype [6], which exhibit low production of IGFBP-3, was associated with increased PCa risk than the wild-type homozygote genotype (AA) and heterozygote genotype (AC), which was consistent with the results of the functional studies mentioned above.…”

“…To date, several studies has been conducted to investigate the association between IGFBP-3 -202A>C polymorphism and PCa risk in men [10,11,12,13,14,15,16,17,18,19]. However, the results remain inconclusive and inconsistent.…”